<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130214">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406860</url>
  </required_header>
  <id_info>
    <org_study_id>201008798</org_study_id>
    <secondary_id>University of Iowa</secondary_id>
    <nct_id>NCT01406860</nct_id>
  </id_info>
  <brief_title>Droperidol Versus Metoclopramide for the Treatment of Primary Headaches</brief_title>
  <official_title>Droperidol Versus Metoclopramide for the Treatment of Primary Headaches in the Emergency Department: A Prospective Randomized, Double-blinded Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if droperidol is equally as effective as
      metoclopramide for treatment of primary headaches in the Emergency Department.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of enrollment/drug shortages
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>Change in pain scores at 60 minutes as measured on the Numerical Rating Scale for Pain (NRS)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Participants will be followed for the duration of their emergency department visit after the initiation of treatment (Average Length of stay in minutes)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour pain score</measure>
    <time_frame>24 hours after discharge from ED</time_frame>
    <description>24 hour pain score (follow-up phone call)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>From the time when the treatment is initiated until the 24 hour follow-up phone survey</time_frame>
    <description>Frequency of adverse effects in each arm</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Primary Headaches (Includes Migraines, Tension, Cluster Headaches)</condition>
  <arm_group>
    <arm_group_label>Droperidol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopramide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diphenhydramine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Droperidol</intervention_name>
    <description>Droperidol 1.25 mg IV x 1, may repeat 0.625 mg if needed at 60 minutes</description>
    <arm_group_label>Droperidol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>Metoclopramide 20 mg IV infusion q30 minutes as needed with a maximum of 4 doses.</description>
    <arm_group_label>Metoclopramide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Diphenhydramine 25 mg IV injection x 1 given with the first dose of metoclopramide IV infusion and repeated x 1 given with the third metoclopramide IV infusion.</description>
    <arm_group_label>Diphenhydramine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old to 65 years old, diagnosis of primary headache

        Exclusion Criteria:

          -  Allergy to study medications, pregnant, breast-feeding, prisoners, non-english
             speaking, not eligible to receive droperidol based on ED protocol (see below),
             patients in whom head trauma, infection, vascular disorders, and disorders of facial
             or cranial structures are suspected

        ED Droperidol Protocol

        Droperidol must NOT be used in patients with any of the following:

          -  Known or suspected QT prolongation, including congenital long QT syndrome

          -  Cardiac Disease [cardiomyopathy, congestive heart failure, hypertension, ischemic
             heart disease, myocardial infarction, bradycardia (&lt; 50 bpm)]

          -  History of the following:

               -  Renal failure

               -  Cerebrovascular disease

               -  Diabetes or hypoglycemia

               -  Alcoholism/alcohol abuse

               -  Pituitary insufficiency

               -  Hypothyroidism

               -  Hypothermia

               -  Anorexia

          -  Advanced age (&gt;65 yrs)

          -  Use of the following medications: digoxin, benzodiazepine, diuretics, IV opiates, or
             other medications known to prolong the QTc interval.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Van Heukelom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Hogrefe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brett Faine, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>September 22, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Brett A Faine</investigator_full_name>
    <investigator_title>Clinical Pharmacy Specialist</investigator_title>
  </responsible_party>
  <keyword>Headaches</keyword>
  <keyword>Migraines</keyword>
  <keyword>Tension headaches</keyword>
  <keyword>Cluster headaches</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Cluster Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Droperidol</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
